======= CARM1 =======


== Gene Information ==
  * **<color #00a2e8>Official Symbol</color>**: CARM1
  * **<color #00a2e8>Official Name</color>**: coactivator associated arginine methyltransferase 1
  * **<color #00a2e8>Aliases and Previous Symbols</color>**: N/A
  * **<color #00a2e8>Entrez ID</color>**: [[https://www.ncbi.nlm.nih.gov/gene/?term=10498|10498]]
  * **<color #00a2e8>UniProt</color>**: [[https://www.uniprot.org/uniprot/Q86X55|Q86X55]]
  * **<color #00a2e8>Interactions</color>**: [[https://thebiogrid.org/search.php?search=CARM1&organism=9606|BioGRID]]
  * **<color #00a2e8>PubMed articles</color>**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20CARM1|Open PubMed]]
  * **<color #00a2e8>OMIM</color>**: [[https://omim.org/entry/603934|Open OMIM]]

== Function Summary ==
  * **<color #00a2e8>Entrez Summary</color>**: N/A
  * **<color #00a2e8>UniProt Summary</color>**:  Methylates (mono- and asymmetric dimethylation) the guanidino nitrogens of arginyl residues in several proteins involved in DNA packaging, transcription regulation, pre-mRNA splicing, and mRNA stability. Recruited to promoters upon gene activation together with histone acetyltransferases from EP300/P300 and p160 families, methylates histone H3 at 'Arg-17' (H3R17me), forming mainly asymmetric dimethylarginine (H3R17me2a), leading to activate transcription via chromatin remodeling. During nuclear hormone receptor activation and TCF7L2/TCF4 activation, acts synergically with EP300/P300 and either one of the p160 histone acetyltransferases NCOA1/SRC1, NCOA2/GRIP1 and NCOA3/ACTR or CTNNB1/beta-catenin to activate transcription. During myogenic transcriptional activation, acts together with NCOA3/ACTR as a coactivator for MEF2C. During monocyte inflammatory stimulation, acts together with EP300/P300 as a coactivator for NF-kappa-B. Acts as coactivator for PPARG, promotes adipocyte differentiation and the accumulation of brown fat tissue. Plays a role in the regulation of pre-mRNA alternative splicing by methylation of splicing factors. Also seems to be involved in p53/TP53 transcriptional activation. Methylates EP300/P300, both at 'Arg- 2142', which may loosen its interaction with NCOA2/GRIP1, and at 'Arg-580' and 'Arg-604' in the KIX domain, which impairs its interaction with CREB and inhibits CREB-dependent transcriptional activation. Also methylates arginine residues in RNA-binding proteins PABPC1, ELAVL1 and ELAV4, which may affect their mRNA- stabilizing properties and the half-life of their target mRNAs. {ECO:0000269|PubMed:16497732, ECO:0000269|PubMed:19405910}.

<button type='primary' size='sm' modal='Pfam_Domains'>Pfam Domains</button>
<button type='primary' size='sm' modal='GO_terms'>GO Terms</button>


<modal id='Pfam_Domains' size='lg' title='Pfam Domains'>
|PrmA|
|MTS|
|Methyltransf 18|
|Methyltransf 9|
|CARM1|
|PRMT5|
</modal>

<modal id='GO_terms' size='lg' title='GO Terms'>
|histone methyltransferase activity (H3-R17 specific)|
|histone H3-R17 methylation|
|regulation of growth plate cartilage chondrocyte proliferation|
|histone H3-R2 methylation|
|protein-arginine N-methyltransferase activity|
|protein-arginine omega-N asymmetric methyltransferase activity|
|peptidyl-arginine methylation, to asymmetrical-dimethyl arginine|
|regulation of mRNA binding|
|histone-arginine N-methyltransferase activity|
|peptidyl-arginine omega-N-methylation|
|protein methyltransferase activity|
|regulation of RNA binding|
|histone methyltransferase activity|
|peptidyl-arginine N-methylation|
|histone arginine methylation|
|peptidyl-arginine methylation|
|lysine-acetylated histone binding|
|intracellular estrogen receptor signaling pathway|
|regulation of bone development|
|protein localization to chromatin|
|peptidyl-arginine modification|
|negative regulation of dendrite development|
|regulation of intracellular estrogen receptor signaling pathway|
|DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest|
|intracellular signal transduction involved in G1 DNA damage checkpoint|
|signal transduction involved in mitotic DNA integrity checkpoint|
|signal transduction involved in mitotic G1 DNA damage checkpoint|
|signal transduction involved in mitotic cell cycle checkpoint|
|signal transduction involved in mitotic DNA damage checkpoint|
|positive regulation of fat cell differentiation|
|protein localization to chromosome|
|mitotic G1 DNA damage checkpoint|
|mitotic G1/S transition checkpoint|
|G1 DNA damage checkpoint|
|nuclear receptor transcription coactivator activity|
|intracellular steroid hormone receptor signaling pathway|
|regulation of cartilage development|
|signal transduction involved in DNA damage checkpoint|
|RNA polymerase II transcription factor complex|
|signal transduction involved in DNA integrity checkpoint|
|signal transduction involved in cell cycle checkpoint|
|endochondral bone morphogenesis|
|regulation of intracellular steroid hormone receptor signaling pathway|
|DNA damage response, signal transduction by p53 class mediator|
|positive regulation of cell cycle arrest|
|beta-catenin binding|
|histone methylation|
|regulation of organ growth|
|mitotic DNA damage checkpoint|
|response to cAMP|
|negative regulation of G1/S transition of mitotic cell cycle|
|negative regulation of protein binding|
|signal transduction in response to DNA damage|
|mitotic DNA integrity checkpoint|
|negative regulation of cell cycle G1/S phase transition|
|regulation of cell cycle arrest|
|bone morphogenesis|
|steroid hormone mediated signaling pathway|
|signal transduction by p53 class mediator|
|regulation of fat cell differentiation|
|DNA damage checkpoint|
|protein alkylation|
|protein methylation|
|response to organophosphorus|
|DNA integrity checkpoint|
|regulation of dendrite development|
|regulation of G1/S transition of mitotic cell cycle|
|response to purine-containing compound|
|positive regulation of NF-kappaB transcription factor activity|
|mitotic cell cycle checkpoint|
|negative regulation of neuron projection development|
|intracellular receptor signaling pathway|
|regulation of cell cycle G1/S phase transition|
|hormone-mediated signaling pathway|
|negative regulation of binding|
|negative regulation of cell projection organization|
|cellular response to steroid hormone stimulus|
|cell cycle checkpoint|
|bone development|
|negative regulation of mitotic cell cycle phase transition|
|transcription regulatory region DNA binding|
|regulation of protein binding|
|negative regulation of neuron differentiation|
|negative regulation of cell cycle phase transition|
|skeletal system morphogenesis|
|macromolecule methylation|
|regulation of animal organ morphogenesis|
|positive regulation of DNA-binding transcription factor activity|
|aging|
|transcription coactivator activity|
|positive regulation of cell cycle process|
|negative regulation of neurogenesis|
|negative regulation of mitotic cell cycle|
|negative regulation of nervous system development|
|methylation|
|negative regulation of cell cycle process|
|response to steroid hormone|
|regulation of developmental growth|
|negative regulation of cell development|
|histone modification|
|covalent chromatin modification|
|positive regulation of cell cycle|
|regulation of binding|
|regulation of lipid metabolic process|
|regulation of mitotic cell cycle phase transition|
|regulation of DNA-binding transcription factor activity|
|regulation of cell cycle phase transition|
|skeletal system development|
|regulation of neuron projection development|
|cellular response to lipid|
|cellular response to organic cyclic compound|
|negative regulation of cell cycle|
|mitotic cell cycle process|
|cellular response to hormone stimulus|
|regulation of mitotic cell cycle|
|regulation of neuron differentiation|
|regulation of growth|
|mitotic cell cycle|
|regulation of plasma membrane bounded cell projection organization|
|chromatin organization|
|viral process|
|negative regulation of cellular component organization|
|regulation of cell projection organization|
|negative regulation of cell differentiation|
|protein localization to organelle|
|regulation of cell cycle process|
|cellular response to DNA damage stimulus|
|symbiotic process|
|regulation of neurogenesis|
|interspecies interaction between organisms|
|response to lipid|
|protein homodimerization activity|
|peptidyl-amino acid modification|
|response to hormone|
|positive regulation of cell population proliferation|
|response to organic cyclic compound|
|regulation of nervous system development|
|regulation of cell development|
|negative regulation of developmental process|
|animal organ morphogenesis|
|positive regulation of cell differentiation|
|cell cycle process|
|response to organonitrogen compound|
|regulation of anatomical structure morphogenesis|
|chromosome organization|
|response to nitrogen compound|
|negative regulation of molecular function|
|regulation of cell cycle|
|negative regulation of multicellular organismal process|
|positive regulation of transcription by RNA polymerase II|
|cellular response to endogenous stimulus|
|cell cycle|
|positive regulation of developmental process|
|response to endogenous stimulus|
|generation of neurons|
|positive regulation of transcription, DNA-templated|
|response to oxygen-containing compound|
|cellular protein localization|
|cellular macromolecule localization|
|regulation of cell population proliferation|
|neurogenesis|
|positive regulation of nucleic acid-templated transcription|
|positive regulation of RNA biosynthetic process|
|intracellular signal transduction|
|cellular response to stress|
|positive regulation of RNA metabolic process|
|positive regulation of molecular function|
|regulation of cell differentiation|
|positive regulation of nucleobase-containing compound metabolic process|
|positive regulation of macromolecule biosynthetic process|
|positive regulation of cellular biosynthetic process|
|positive regulation of gene expression|
|positive regulation of biosynthetic process|
</modal>
\\

 === CRISPR Data ===
<button type='primary' size='small' modal='Compound_Hit'>Compound Hit</button>
<button type='default' size='small' modal='Most_Correlated_Genes'>Most Correlated Genes in Chemogenomics</button>
<button type='primary' size='small' modal='Essential_Avana'>Tissues where Essential in the Avana Dataset (DepMap 20Q1)</button>

<modal id='Compound_Hit' size='lg' title='Compound Hit'>
^Screen^Score^
|[[:results:exp499|LY2090314 0.003μM R08 exp499]]|-2.91|
|[[:results:exp226|Cerivastatin 0.15μM R05 exp226]]|-2.9|
|[[:results:exp455|Benzoate 10000μM R08 exp455]]|-2.48|
|[[:results:exp410|THZ531 0.11 to 0.125μM on day4 R07 exp410]]|-2.4|
|[[:results:exp497|Lead acetate 2000μM R08 exp497]]|-2.35|
|[[:results:exp84|UM0125461 0.74μM R02 exp84]]|-2.32|
|[[:results:exp282|Fluvastatin 2.2μM R06 exp282]]|-2.29|
|[[:results:exp412|THZ531 0.11 to 0.125 to 0.35μM on day4 then day6 R07 exp412]]|-2.19|
|[[:results:exp264|Arsenate 40μM R06 exp264]]|-2.02|
|[[:results:exp409|THZ531 0.11μM R07 exp409]]|-1.99|
|[[:results:exp187|proTAME 5μM R04 exp187]]|-1.98|
|[[:results:exp505|ML-792 0.2μM R08 exp505]]|-1.97|
|[[:results:exp99|NFN1 0.4μM R03 exp99]]|-1.96|
|[[:results:exp500|LY2090314 0.003μM R08 exp500 no dilution day6]]|-1.91|
|[[:results:exp177|Apcin 25μM plus proTAME 2μM R04 exp177]]|-1.89|
|[[:results:exp356|Docosahexaenoic-acid 50μM R07 exp356]]|-1.84|
|[[:results:exp134|MS023 2μM R03 exp134]]|-1.83|
|[[:results:exp407|Thapsigargin 0.005μM R07 exp407]]|-1.83|
|[[:results:exp330|5-Azacytidine 2μM R07 exp330]]|-1.8|
|[[:results:exp391|Pomalidomide 20μM R07 exp391]]|-1.8|
|[[:results:exp5|Alpha-Amanitin 0.5μM R00 exp5]]|-1.79|
|[[:results:exp317|Geldanamycin 0.015 to 0.05μM on day4 R07 exp317]]|-1.71|
|[[:results:exp211|AICAR 240μM R05 exp211]]|1.72|
|[[:results:exp35|TRAIL 5ng/ml R00 exp35]]|1.82|
|[[:results:exp128|GSK591 2.6μM R03 exp128]]|1.83|
|[[:results:exp125|GSK461364A 0.005μM R03 exp125]]|1.93|
|[[:results:exp68|Clomiphene 4.4μM R02 exp68]]|1.96|
|[[:results:exp36|TRAIL 50ng/ml R00 exp36]]|1.97|
|[[:results:exp454|Bafilomycin-A1 0.009μM R08 exp454]]|2.17|
|[[:results:exp89|Vemurafenib 6.6μM R02 exp89]]|3.5|
|[[:results:exp354|Diepoxybutane 3μM R07 exp354]]|3.53|
|[[:results:exp434|Vemurafenib 6.6μM R08 exp434]]|4.2|
</modal>

<modal id='Most_Correlated_Genes' size='lg' title='Most Correlated Genes in Chemogenomics'>
No correlation found to any other genes in chemogenomics.
</modal>

<modal id='Essential_Avana' size='lg' title='Tissues where Essential in the Avana Dataset (DepMap 20Q1)'>
Global Fraction of Cell Lines Where Essential: 7/726
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|1/28|
|bone|0/25|
|breast|0/33|
|central nervous system|0/56|
|cervix|0/4|
|colorectal|0/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|0/15|
|kidney|0/21|
|liver|0/20|
|lung|1/75|
|lymphocyte|1/14|
|ovary|0/26|
|pancreas|0/24|
|peripheral nervous system|0/16|
|plasma cell|2/15|
|prostate|0/1|
|skin|0/24|
|soft tissue|0/7|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|0/29|
|uterus|0/5|
</modal>

== Essentiality in NALM6  ==
    * **<color #00a2e8>Essentiality Rank</color>**: 8114
    * **<color #00a2e8>Expression level (log2 read counts)</color>**: 6.23 
<button type='primary' size='small' modal='Dist_expr'>Expression Distribution</button>
<modal id='Dist_expr' size='lg' title='CARM1 Expression in NALM6 Cells: 6.23'>
{{:chemogenomics:nalm6 dist.png?nolink |}}
</modal>